{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:46:25Z","timestamp":1791287185961,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.mbs.2021.108756","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T19:42:38Z","timestamp":1638819758000},"page":"108756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Machine learning for mathematical models of HCV kinetics during antiviral therapy"],"prefix":"10.1016","volume":"343","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4275-257X","authenticated-orcid":false,"given":"Alexander","family":"Churkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-3266","authenticated-orcid":false,"given":"Asher","family":"Uziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-3379","authenticated-orcid":false,"given":"Ashish","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Zakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Cotler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Etzion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-5160","authenticated-orcid":false,"given":"Horacio G.","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-5302","authenticated-orcid":false,"given":"Danny","family":"Barash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.mbs.2021.108756_b1","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mbs.2021.108756_b2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."},{"issue":"9916","key":"10.1016\/j.mbs.2021.108756_b3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"9973","key":"10.1016\/j.mbs.2021.108756_b4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mbs.2021.108756_b5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187409","article-title":"HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients","volume":"12","author":"Canini","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mbs.2021.108756_b6","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","article-title":"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir","volume":"64","author":"Dahari","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.mbs.2021.108756_b7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/liv.14014","article-title":"Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis","volume":"39","author":"Gambato","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.mbs.2021.108756_b8","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000587","article-title":"Acute kidney injury presenting as hepatorenal syndrome in the setting of glecaprevir\/pibrentasvir treatment for hepatitis C","volume":"8","author":"Fansiwala","year":"2021","journal-title":"ACG Case Rep. J."},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b9","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mbs.2021.108756_b10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104862","article-title":"Modeling based response guided therapy in subjects with recent hepatitis C infection","volume":"180","author":"Gorstein","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.mbs.2021.108756_b11","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa219","article-title":"Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir\/pibrentasvir may identify patients for ultra-short treatment duration","author":"Dasgupta","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"5255","key":"10.1016\/j.mbs.2021.108756_b12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"issue":"6510","key":"10.1016\/j.mbs.2021.108756_b13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"issue":"5386","key":"10.1016\/j.mbs.2021.108756_b14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.mbs.2021.108756_b15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11901-011-0101-7","article-title":"Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28b","volume":"10","author":"Dahari","year":"2011","journal-title":"Curr. Hepat. Rep."},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/imr.12686","article-title":"Modeling the dynamics of hepatitis B infection, immunity, and drug therapy","volume":"285","author":"Ciupe","year":"2018","journal-title":"Immunol. Rev."},{"issue":"20","key":"10.1016\/j.mbs.2021.108756_b17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123052","article-title":"Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design","volume":"3","author":"Ke","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12700","article-title":"Introduction to modeling viral infections and immunity","volume":"285","author":"Perelson","year":"2018","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.mbs.2021.108756_b19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtbi.2007.03.006","article-title":"Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy","volume":"247","author":"Dahari","year":"2007","journal-title":"J. Theoret. Biol."},{"issue":"3","key":"10.1016\/j.mbs.2021.108756_b20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2010.03.019","article-title":"Pharmacodynamics of PEG-IFN-alpha-2a in HIV\/HCV co-infected patients: implications for treatment outcomes","volume":"53","author":"Dahari","year":"2010","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.mbs.2021.108756_b21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/liv.12692","article-title":"Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics","volume":"35","author":"Dahari","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.mbs.2021.108756_b22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.antiviral.2019.01.017","article-title":"A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C","volume":"163","author":"Koh","year":"2019","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.mbs.2021.108756_b23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7326\/0003-4819-123-5-199509010-00001","article-title":"Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications","volume":"123","author":"Gretch","year":"1995","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.mbs.2021.108756_b24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00042737-200208000-00004","article-title":"Viral kinetics of hepatitis C virus RNA in patients with chronic hepatitis C treated with 18 MU of interferon alpha daily","volume":"14","author":"Sentjens","year":"2002","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.mbs.2021.108756_b25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.mbs.2021.108756_b26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/bulm.2001.0266","article-title":"HIV-1 infection and low steady state viral loads","volume":"64","author":"Callaway","year":"2002","journal-title":"Bull. Math. Biol."},{"issue":"2","key":"10.1016\/j.mbs.2021.108756_b28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0025-5564(03)00058-0","article-title":"Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity","volume":"184","author":"Huang","year":"2003","journal-title":"Math. Biosci."},{"issue":"S2","key":"10.1016\/j.mbs.2021.108756_b29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jvh.45_12923","article-title":"Modeling time to cure after short\u2013duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: the FOURward study","volume":"25","author":"Deng","year":"2018","journal-title":"J. Viral Hepat."},{"issue":"1\u201311","key":"10.1016\/j.mbs.2021.108756_b30","article-title":"Nonlinear diffusion on an extended neighborhood","volume":"52","author":"Barash","year":"2005","journal-title":"Appl. Numer. Math."},{"key":"10.1016\/j.mbs.2021.108756_b31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2018.03.011","article-title":"Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics","volume":"300","author":"Reinharz","year":"2018","journal-title":"Math. Biosci."},{"issue":"2","key":"10.1016\/j.mbs.2021.108756_b32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1090\/qam\/10666","article-title":"A method for the solution of certain non-linear problems in least squares","volume":"2","author":"Levenberg","year":"1944","journal-title":"Quart. Appl. Math."},{"key":"10.1016\/j.mbs.2021.108756_b33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1137\/0111030","article-title":"An algorithm for least-squares estimation of nonlinear parameters","volume":"11","author":"Marquardt","year":"1963","journal-title":"J. Soc. Ind. Appl. Math."},{"issue":"3","key":"10.1016\/j.mbs.2021.108756_b34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"Rong","year":"2013","journal-title":"PLoS Comput. Biol."},{"issue":"10","key":"10.1016\/j.mbs.2021.108756_b35","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1007\/s11538-019-00644-7","article-title":"A parameter estimation method for multiscale models of hepatitis C virus dynamics","volume":"81","author":"Reinharz","year":"2019","journal-title":"Bull. Math. Biol."},{"issue":"9","key":"10.1016\/j.mbs.2021.108756_b36","article-title":"Efficient methods for parameter estimation of ordinary and partial differential equation models of viral hepatitis kinetics","volume":"8","author":"Churkin","year":"2020","journal-title":"Mathematics (Basel)"},{"issue":"8","key":"10.1016\/j.mbs.2021.108756_b37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1109\/34.709601","article-title":"The random subspace method for constructing decision forests","volume":"20","author":"Ho","year":"1998","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"10.1016\/j.mbs.2021.108756_b39","series-title":"Neural Networks: A Comprehensive Foundation","author":"Haykin","year":"1998"},{"key":"10.1016\/j.mbs.2021.108756_b40","series-title":"Data Mining: Practical Machine Learning Tools and Techniques","author":"Witten","year":"2011"},{"issue":"1","key":"10.1016\/j.mbs.2021.108756_b41","first-page":"3","article-title":"On identifiability of nonlinear ODE models and applications in viral dynamics","volume":"53","author":"Miao","year":"2011","journal-title":"SIAM Rev. Soc. Ind. Appl. Math."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556421001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556421001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:23:42Z","timestamp":1758417822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556421001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S0025556421001577"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2021.108756","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Machine learning for mathematical models of HCV kinetics during antiviral therapy","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2021.108756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108756"}}